asterias biotherapeutics receives u.s. fda clearance to initiate phase 1/2a clinical trial of ast-opc1 in patients with cervical complete spinal cord injury
August 27, 2014
Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration
FDA Clearance Triggers Definitive Contract Finalization with California Institute of Regenerative Medicine (CIRM) to Begin $14.3 Million in Trial Funding
I just posted a short list of some of the highlights from todays webcast. Great future for this one!
...which results in a WHOPPING 30-penny spike in ASTY pps....and an "IGNORE" for "btimnextmicrosoft", for pumping other stocks on this message board.